Anyone know when stelara is going to kick in I'm dying in agony over here
seen from United Kingdom

seen from United States
seen from China

seen from United States
seen from Kenya

seen from United States

seen from United States

seen from United States

seen from United Kingdom
seen from China

seen from United States

seen from Malaysia
seen from China
seen from China
seen from China
seen from United States

seen from United States

seen from United Kingdom
seen from United States
seen from United States
Anyone know when stelara is going to kick in I'm dying in agony over here
Yesintek Gets FDA approval as the sixth biosimilar to Stelara (Ustekinumab), offering an effective and affordable treatment for Crohn's dise
Colite Ulcerosa: Ustekinumab mostra remissione duratura dei sintomi a 3 anni
Janssen, l’azienda farmaceutica del gruppo Johnson & Johnson, ha presentato, al 16° Congresso dell’European Crohn’s and Colitis Organisation (ECCO), nuovi dati su ustekinumab, provenienti dall’estensione a lungo termine (LTE) dello studio di Fase III UNIFI. Giunti alla settimana 152, poco meno di tre anni, mostrano che tra i 348 pazienti adulti con colite ulcerosa (UC) attiva da moderata a grave…
Bimekizumab superior to ustekinumab for plaque psoriasis
Bimekizumab superior to ustekinumab for plaque psoriasis
(HealthDay)—For moderate-to-severe plaque psoriasis, bimekizumab is more efficacious than ustekinumab and placebo, according to a study published in the Feb. 6 issue of The Lancet. Kristian Reich, M.D., from the University Medical Center Hamburg-Eppendorf in Germany, and colleagues compared the efficacy and safety of bimekizumab with placebo and ustekinumab in patients with moderate-to-severe…
View On WordPress
Ustekinumab efficace e sicuro nella colite ulcerosa
Ustekinumab di Janssen (Stelara®), già disponibile in Italia per la malattia di Crohn e già approvato nell’Unione Europea per la colite ulcerosa, si è dimostrato efficace e sicuro nel trattamento a due anni nei pazienti adulti con colite ulcerosa da moderata a grave.
Questo è quanto emerge dai risultati dell’estensione a lungo termine dello studio di fase 3 UNIFI, presentati al 27° congresso…
View On WordPress
Ustekinumab, Obat Terapi Biologis Bertarget Interleukin Pertama Untuk Penyakit Crohn
Ustekinumab, Obat Terapi Biologis Bertarget Interleukin Pertama Untuk Penyakit Crohn
Majalah Farmasetika (V1N8-Oktober 2016). Jansen Pharmaceutical kemarin (26/9) mengumumkan bahwa Food and Drug Administration (FDA) telah menyetujui STELARA® (ustekinumab) untuk pengobatan penyakit Crohn aktif dari moderat hingga parah pada orang dewasa (18 tahun atau lebih tua) yang telah gagal atau tidak toleran untuk pengobatan dengan imunomodulator atau kortikosteroid tetapi pengobatan tidak…
View On WordPress